Bartlett, Nancy L <br/><br/>
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.  [electronic resource] 

 -  Leukemia & lymphoma  07 2017 
 - 1607-1616 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428194.2016.1256481  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers<br/>Brentuximab Vedotin<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Immunoconjugates--administration & dosage<br/>Immunohistochemistry<br/>Ki-1 Antigen--metabolism<br/>Lymphoma, Large B-Cell, Diffuse--diagnosis<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Recurrence<br/>Retreatment<br/>Treatment Outcome<br/>Young Adult